Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

VectivBio

Request full access

Clinical-stage biotechnology company focused on rare conditions with a well-defined biology that can be targeted with transformational therapeutics

Basel, SwitzerlandFounded 2019Biotech & Life Sciences

About VectivBio

VectivBio is a biotechnology company dedicated to developing transformative therapies for severe rare diseases. Headquartered in Basel, Switzerland, with business operations in the New York area, VectivBio focuses on identifying and developing treatments for conditions with well-defined biology that can be targeted with tailored therapies. The company serves patients suffering from severe rare diseases, such as Short Bowel Syndrome with Intestinal Failure (SBS-IF), a rare and debilitating condition. VectivBio operates in the global biopharmaceutical market, leveraging its expertise in bioprocess development and rare disease drug development to create innovative solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the successful launch and lifecycle management of biotech and small molecule products. The company's patient-centric approach ensures that the needs and experiences of patients are at the forefront of its mission to improve lives.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

VectivBio in the Basel ecosystem

Live from Dealroom

The VectivBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • Novo Holdings
  • Pfizer
  • OrbiMed
  • Versant Ventures
  • Eventide Asset Management
  • Cormorant Capital
  • Bpifrance
  • Tekla Capital Management
  • Citadel
  • Cowen Group
  • Inserm Transfert Initiative

Series B and later2 investors entered at this stage

  • Kreos Capital
  • Forbion Capital Partners
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$5M

8 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See VectivBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.